QM-3, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 150 mcg/mL . Atropine 0.2 mg/mL, 1...
FDA Drug Recall #D-0811-2022 — Class II — April 4, 2022
Recall Summary
| Recall Number | D-0811-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 4, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Olympia Compounding Pharmacy dba Olympia Pharmacy |
| Location | Orlando, FL |
| Product Type | Drugs |
| Quantity | 1679 vials |
Product Description
QM-3, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 150 mcg/mL . Atropine 0.2 mg/mL, 10 mL Multi-Dose vial, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0019-10.
Reason for Recall
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
Distribution Pattern
Distributed Nationwide in the USA
Lot / Code Information
Lots: E42B12 BUD: 5/12/2022, E42C12 BUD: 5/12/2022, E42D12 BUD: 5/12/2022, H24B23 BUD: 8/23/2022, H24C23 BUD: 8/23/2022, H24D23 BUD: 8/23/2022
Other Recalls from Olympia Compounding Pharmacy dba Olym...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0904-2022 | Class II | Sodium Bicarbonate 8.4% MDV Injection, Multi-Do... | May 9, 2022 |
| D-0930-2022 | Class II | Lidocaine 2% (20 mg/mL), Multi-Dose 30 mL vial ... | May 9, 2022 |
| D-0910-2022 | Class II | T-106 Papaverine 30 mg/mL Phentolamine 1 mg/mL ... | May 9, 2022 |
| D-0905-2022 | Class II | Sodium Selenite 200 mg/mL, Multi-Dose 30 mL via... | May 9, 2022 |
| D-0902-2022 | Class II | Sermorelin Acetate Lyophilized powder for recon... | May 9, 2022 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.